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Introduction
The Na+/I- symporter (NIS) is an intrinsic plasma membrane 
glycoprotein that mediates the active uptake of I- in the thyroid 
and other tissues such as salivary glands, gastric mucosa and 
lactating mammary gland. Physiologically, NIS is expressed in the 
breast exclusively during gestation and lactation. In vitro and in 
vivo studies confirmed that lactogenic hormones, including pro-
lactin, can induce functional NIS expression in mammary tissue. 
Hyperprolactinemia is common in patients with end-stage renal 
disease (ESRD).
Clinical case
A 42-year-old woman with papillary thyroid cancer and ESRD 
treated with haemodialysis underwent 131I adjuvant therapy after 
rh-TSH (Thyrogen®) stimulation. 
After 131I application, the patient underwent dialysis sessions in 
the nephrology department every second day after 131I therapy. 
A posttherapy whole-body scan performed 96 hours after adminis-
tration of 100 mCi/3700MBq 131I showed radioiodine accumulation 
in thyroid bed and chest (Fig. 1), that in single-photon emission 
computed tomography fusion imaging (SPECT/CT) was confirmed 
as intense and symmetrical breasts uptake (Fig. 2). The patient 
had her last menstruation 5 years ago and denied galactorrhoea. 
The prolactin level measured after 131I therapy was 100.98 ng/mL 
(reference range 5.18–26.53 ng/mL). 
The ultrasound of the mammary glands and conventional 
mammography was without any abnormalities. 
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Figure 1. Post therapeutic 131I planar whole-body scan showed 
symmetric and intense iodine uptake in mammary glands
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Due to NIS expression in lactating mammary tissue breast-
feeding is an absolute contraindication to radioiodine therapy. 
The time interval between completed breastfeeding and radioiodine 
treatment should be at least six weeks. NIS expression has been 
also demonstrated in benign and malignant breast lesions, however, 
that was not the case of the presented patient. 
The major causes of hyperprolactinemia in patients with ESRD 
is the reduced renal clearance of prolactin (which level does not 
decrease significantly in response to haemodialysis) and enhanced 
prolactin secretion by the pituitary due to lactotrophic resistance 
Although each year about 10 patients on haemodialysis are treated 
with radioiodine, this was the first patient on haemodialysis and 
radioiodine uptake in breasts. The explanation for it could be the 
young age of the patient since the other ones were much older 
(median 60 years of age). One cannot exclude that the mammary 
gland in younger women is more sensitive to prolactin stimulation 
due to the increased amount of epithelial tissue. 
Prolactin measurement and stimulation of the D2 receptor 
with dopamine agonists should be considered in young female 
patients with ESRD who are planned for radioiodine treatment. 
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Figure 2. Image fusion of CT and iodine SPECT scan of the thoracic 
region clearly demonstrated the radioiodine uptake in the breasts
